A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF AC-201 IN SUBJECTS WITH GOUT
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 127
- 试验地点
- 1
- 主要终点
- Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL
研究概览
简要总结
The study is designed to test the urate-lowering effect, safety, and tolerability of AC-201CR in an initial dosing period, followed by the addition of a ULT to test the efficacy and safety of the combination and prophylaxis of gout flares during ULT.
详细描述
AC-201CR is a control released formulation of AC-201 that in previous clinical studies showed potential dual effects in both reducing serum uric acid (sUA) and gout flares. The mechanism of action of AC-201 includes the inhibition of the production and activity of caspase-1 and interleukin-1β (IL-1β), and selective inhibition of re-absorption transporters in the kidney. The goal of gout treatment is to reduce serum uric acid (sUA) concentrations below the urate solubility limit while avoiding acute gout flares. However, the initiation of urate-lowering therapy (ULT) increases the occurrence of acute gouty arthritis flares. IL-1β plays a key role in mediating this inflammatory response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female age 20 to 65 years, inclusive.
- •Meets ≥6 of the 12 American College of Rheumatology preliminary criteria (1977) for the classification of acute arthritis of primary gout (Appendix 2), OR have proven tophus or documented monosodium urate (MSU) crystals in the joint fluid.
- •Serum uric acid ≥7.5 mg/dL and ≤10 mg/dL at screening with ≥1 gouty arthritis flare within one year prior to screening, OR serum uric acid ≥9 mg/dL and ≤10 mg/dL at screening with or without prior gout flares.
排除标准
- •Use of allopurinol, febuxostat, benzbromarone, probenecid, or sulfinpyrazone within 2 weeks prior to screening.
- •Occurrence of a gouty arthritis flare within 1 week prior to screening or during the screening period through baseline.
- •Use of colchicine within 1 week prior to screening.
- •Use of Glucocorticoids, NSAIDs or COX-2 inhibitors within 1 week prior to screening.
- •Allergy, contraindication, or intolerance to febuxostat.
- •Severe renal impairment.
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) concentration >2 times the upper limit of laboratory normal range (>2x ULN) at screening.
研究组 & 干预措施
Placebo
Placebo plus Febuxostat
干预措施: Placebo (Drug)
Placebo
Placebo plus Febuxostat
干预措施: Febuxostat (Drug)
AC-201
AC-201 CR tablet plus Febuxostat
干预措施: AC-201 (Drug)
AC-201
AC-201 CR tablet plus Febuxostat
干预措施: Febuxostat (Drug)
结局指标
主要结局
Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL
时间窗: 8 weeks
次要结局
未报告次要终点